Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma

20168 citationsJournal Articlebronze Open Access

Authors

Martin Koskas · Délégation Paris 7

Jeroen Depreeuw · KU Leuven

Stijn Moens · KU Leuven

Daniela Annibali · KU Leuven

Tine Cuppens · KU Leuven

Philippe Moerman · KU Leuven

Diether Lambrechts · VIB-KU Leuven Center for Microbiology

Abstract

Even associated with paclitaxel, HER2-positive endometrial carcinomas poorly responded to trastuzumab. This report underlines the low accuracy of HER2 positivity to predict response of endometrial cancer to combined targeted therapy using trastuzumab and paclitaxel.

Topics & Keywords

HER2/EGFR in Cancer Research Cell Adhesion Molecules Research Angiogenesis and VEGF in Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Anticancer Research

Volume 36, Issue 10, pp. 5381-5384

DOI: 10.21873/anticanres.11112

Field-Weighted Citation Impact: 0.46